| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.8 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |